NGF-expressing neurons support trophic maintenance, axonal integrity, and circuit stability in central and peripheral systems through coordinated signaling across TrkA and p75NTR receptor axes[1][2]. In neurodegeneration, NGF-neuron biology is particularly relevant to basal forebrain cholinergic vulnerability, neuroinflammatory stress responses, and impaired trophic transport in aging networks[3][4].
| Property | Value |
|---|---|
| Category | Neurotrophin-producing neurons |
| Core ligand | Nerve Growth Factor (NGF) |
| Primary receptors | TrkA (NTRK1), p75NTR |
| High-relevance circuits | Basal forebrain-cortical/hippocampal projection systems, nociceptive pathways |
| Key disease links | Alzheimer's Disease, Parkinson's Disease, peripheral neuropathies |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000693 | neurogliaform cell |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000693 | neurogliaform cell | Exact |
NGF neurons synthesize proNGF and mature NGF, and biological output depends on local processing as well as receptor context[2:1][5]. Mature NGF favors TrkA-mediated trophic programs, while proNGF in p75NTR-dominant environments can shift toward stress signaling and apoptosis susceptibility[5:1][6].
Key downstream effects include:
This dual-axis behavior helps explain why NGF biology can appear protective in one cellular compartment and maladaptive in another.
NGF signaling is tightly linked to the phenotype and persistence of basal forebrain cholinergic neurons, which project broadly to cortex and hippocampus to regulate attention and memory-state modulation[3:1][7]. Failure of this trophic axis is a long-standing mechanistic hypothesis for early AD-related cognitive decline.
Beyond classic cholinergic targets, NGF neurons influence local microcircuit trophic tone and synaptic maintenance in learning-relevant networks. These effects intersect with broader Neurotrophin Signaling in Neurodegeneration, including crosstalk with BDNF-mediated plasticity programs.
In peripheral and brainstem-connected pathways, NGF neuron signaling contributes to nociceptive sensitization and autonomic adaptation, making NGF pathways relevant for symptom domains that overlap with neurodegenerative disease (pain, autonomic dysfunction, sleep disruption)[8].
AD is associated with impaired retrograde NGF transport, altered proNGF/mature NGF balance, and reduced trophic support to cholinergic projection neurons[4:1][7:1]. This provides a mechanistic bridge from molecular pathology to network-level cholinergic failure and progressive memory dysfunction.
Although less central than dopaminergic trophic pathways in PD, NGF-neuron dysfunction may contribute to non-dopaminergic symptom burden, including cognitive and autonomic components[9]. In mixed pathologies, NGF-p75 signaling may amplify inflammatory and degenerative signaling cascades.
Clinical and preclinical programs have tested gene and delivery approaches to restore NGF signaling in vulnerable circuits, with variable efficacy constrained by targeting and distribution challenges[10][11]. Ongoing strategies prioritize local delivery and receptor-selective modulation as part of Growth Factor Therapies for Neurodegeneration.
Interpretation of NGF measures (CSF, plasma, tissue) requires caution because compartment, processing state (proNGF vs mature NGF), and receptor expression shift disease meaning. Experimental designs that pair NGF quantification with TrkA/p75 context and cholinergic phenotyping are more mechanistically informative[5:2][12].
The study of Ngf Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987. ↩︎
Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nature Reviews Neuroscience. 2003. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Journal of Alzheimer's Disease. 2008. ↩︎ ↩︎
Cattaneo A, Calissano P. Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis. Molecular Neurobiology. 2012. ↩︎ ↩︎
Hempstead BL. [The many faces of p75NTR](https://doi.org/10.1016/S0959-4388(02). Current Opinion in Neurobiology. 2002. ↩︎ ↩︎ ↩︎
Ibanez CF, Simi A. p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradoxes and potentials. Experimental Neurology. 2011. ↩︎
Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine. 2005. ↩︎ ↩︎
Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & Therapeutics. 2013. ↩︎
Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Translational Neurodegeneration. 2015. ↩︎
Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 1998. ↩︎
Williams BJ, Eriksdotter Jonhagen M, Granholm AC. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006. ↩︎
Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behavioural Brain Research. 2010. ↩︎